Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicentre, Randomised Trial Comparing Combination Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC)

NCT02722369 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT02722369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02722369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicentre, Randomised Trial Comparing Combination Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC)
Lead sponsor
University College, London
Phase
Phase 2
Overall status
Terminated
Start date
March 14, 2017
Completion date
March 12, 2021
Enrollment
72 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer